In November 2005, Boehringer Ingelheim and the U.S. Food and Drug Administration notified healthcare professionals of revisions to PRECAUTIONS and ADVERSE REACTIONS sections of the prescribing information for Flomax (tamsulosin HCl), indicated for the treatment of the signs and symptoms of BPH. A surgical condition termed Intraoperative Floppy Iris Syndrome (IFIS) has been observed during phacoemulsification cataract surgery in some patients treated with alpha-1 blockers including Flomax. Most of these reports were in patients taking the alpha-1 blocker when IFIS occurred, but in some cases alpha-1 blocker had been stopped prior to surgery.

Change Notice: Any information related to Prostate-Specific Antigen (PSA) in the following guideline may have been revised in the American Urological Association’s (AUA) PSA Best Practice Statement: 2009 Update. In the case of any discrepancy in recommendations between guidelines pertaining to PSA, please refer to the AUA’s PSA Best Practice Statement: 2009 Update for the latest AUA recommendation regarding PSA testing.
AUA Guideline on the Management of Benign Prostatic Hyperplasia:

PREFACE

In 1994, under the auspices of the United States Department of Health and Human Services Agency for Health Care Policy and Research (AHCPR; now known as the Agency for Healthcare Research and Quality), the Benign Prostatic Hyperplasia Guideline Panel published evidence-based guidelines for the diagnosis and treatment of benign prostatic hyperplasia (BPH). Subsequently, the AHCPR reorganized; updating the previously published guidelines was no longer an objective of the Agency. Given the importance of BPH to urologists and to their patients, the American Urological Association (AUA) Practice Guidelines Committee elected to update the AHCPR document through a similar, multidisciplinary, evidence-based approach. A new panel, the AUA BPH Guideline Update Panel (the Panel) was appointed.

During its initial discussions, the Panel used a consensus approach to determine if the basic framework of the 1994 AHCPR guideline was still appropriate. Except for the status of three tests in the initial evaluation of patients—serum creatinine, prostate-specific antigen, and urine cytology measurements—the use of supplementary validated symptom assessment instruments and discussion of treatment options with the patient before pressure-flow testing, the Panel believed there was no new body of evidence to suggest that the previously published diagnosis (evaluation) decision diagram be altered. Moreover, the AUA Panel felt that the fundamental approach to treatment selection—*informed patient decision making*—should remain a standard.

The landscape of BPH treatment options had changed significantly since 1994. New forms of medical and minimally invasive treatments had been approved by the Food and Drug Administration (FDA) while other therapies had become obsolete. Balloon dilation of the prostate, for example was a recommended treatment option in 1994, and essentially a nonexistent
procedure in 2001. More importantly, the overall quality of clinical research methodologies and the validity of outcomes data had improved substantially. Randomized, controlled trials, the gold standard of treatment evaluation, were rare in the 1994 analysis, but had been published in significant numbers since. For these reasons, the Panel focused its energies on revisiting the evidence-based treatment recommendations but not the recommendations for the diagnosis of BPH.
# Chapter 1: Diagnosis and Treatment Recommendations

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>1-1</td>
</tr>
<tr>
<td>Definitions and terminology</td>
<td>1-2</td>
</tr>
<tr>
<td>Methodology</td>
<td>1-3</td>
</tr>
<tr>
<td>Diagnostic Evaluation of benign prostatic hyperplasia</td>
<td>1-5</td>
</tr>
<tr>
<td>Initial Evaluation</td>
<td>1-8</td>
</tr>
<tr>
<td>Symptom Assessment</td>
<td>1-10</td>
</tr>
<tr>
<td>Optional Diagnostic Tests</td>
<td>1-12</td>
</tr>
<tr>
<td>Initial management and discussion of treatment options with the patient</td>
<td>1-14</td>
</tr>
<tr>
<td>Management of Patients With Bothersome Moderate to Severe Symptoms</td>
<td>1-14</td>
</tr>
<tr>
<td>Management of Patient with Bothersome Moderate to Severe Symptoms</td>
<td>1-14</td>
</tr>
<tr>
<td>Optional Diagnostic Test for Patients Who Choose Invasive Therapy</td>
<td>1-17</td>
</tr>
<tr>
<td>Treatment Recommendations</td>
<td>1-20</td>
</tr>
<tr>
<td>Recommended Therapies</td>
<td>1-21</td>
</tr>
<tr>
<td>Watchful Waiting</td>
<td>1-21</td>
</tr>
<tr>
<td>Medical Treatment</td>
<td>1-21</td>
</tr>
<tr>
<td>Alpha-adrenergic blocker therapy</td>
<td>1-22</td>
</tr>
<tr>
<td>5 Alpha-reductase inhibitor therapy</td>
<td>1-23</td>
</tr>
<tr>
<td>Combination therapy</td>
<td>1-25</td>
</tr>
<tr>
<td>Minimally Invasive Therapies</td>
<td>1-26</td>
</tr>
</tbody>
</table>
Chapter 2: Methodology

Introduction 2-1

Defining the topics, the literature search and data extraction 2-3

Defining the Topics 2-3

The Literature Search 2-5

Data Extraction 2-5

Evidence Combination 2-6
Chapter 3: Results of the Treatment Outcomes Analyses

Introduction 3-1

Types of treatment outcomes 3-1

Efficacy Outcomes 3-2

Symptom Scores 3-2

Validated symptom scores 3-2

Nonvalidated symptom scores 3-3

Custom-made symptom scores 3-3

Modified symptom scores 3-3

Peak Urinary Flow Rate 3-4

Quality-of-life Scoring Instruments 3-5

Efficacy Outcomes Not Analyzed 3-6

Postvoid residual urine 3-6

Invasive pressure-flow studies 3-7

Prostate volume 3-7

Serum prostate-specific antigen 3-10

Adverse Events Outcomes 3-11

Types of treatment interventions 3-11
Watchful Waiting 3-12
Medical Therapies 3-13
Minimally Invasive Therapies 3-14
Surgical Therapies 3-15
Outcomes Analyzed 3-15
Efficacy outcomes-results of analyses 3-17
Medical Therapies 3-18
  AUA Symptom Index 3-18
    Alpha blockers 3-18
    5 Alpha-reductase inhibitors 3-20
    Combination therapy 3-21
  Peak Urinary Flow Rate 3-23
  BPH Impact Index 3-25
  Disease Specific Quality of Life Question 3-26
Minimally Invasive Therapies 3-27
  AUA Symptom Index 3-28
  Peak Urinary Flow Rate 3-30
  BPH Impact Index 3-31
  Disease Specific Quality of Life Question 3-31
Surgical Therapies 3-32
  AUA Symptom Index 3-33
  Peak Urinary Flow Rate 3-34
  Disease Specific Quality of Life Question 3-35
Comparison of Efficacy Outcomes by Treatment Intervention 3-36

Adverse events outcomes-results of analyses 3-39

Perioperative Mortality 3-41

Medical Therapies 3-43

Asthenia 3-43

Dizziness 3-45

Headache 3-47

Hypotension 3-48

Asymptomatic hypotension 3-49

Symptomatic hypotension 3-50

Symptomatic postural hypotension 3-51

Syncope 3-52

Respiratory/Nasal Congestion 3-54

Sexually Related Adverse Events 3-55

Erectile dysfunction 3-55

Ejaculatory dysfunction 3-60

Libido problems 3-62

Other 3-59

Cardiovascular adverse events 3-59

Breast adverse events 3-60

Short-term Adverse Events Reported With Minimally Invasive
And Invasive Therapies 3-61

Intraoperative Complications 3-61
Hematuria 3-62
Transfusion 3-64
Infections/Urinary Tract Infections 3-66
Irritative Voiding Symptoms 3-68
Acute Urinary Retention 3-71

Long-term Adverse Events Reported With Minimally Invasive And Invasive Therapies 3-74
Urinary Incontinence 3-74
Secondary Procedures 3-76
Bladder Neck Contracture/Urethral Stricture 3-79
Sexual Dysfunction 3-81

Appendix 3

Chapter 4: Research and Future Directions

Introduction 4-1
Etiology and pathophysiology 4-2
Natural history and epidemiology 4-3
Diagnosis and initial management 4-4
Therapeutic Interventions 4-4
Economics 4-5
Reporting and publication issues 4-6

Appendix 4